Tumor vascular ECs can reduce the recruitment and activation of cytotoxic T lymphocytes (CTLs) by expressing a variety of immunosuppressive molecules, such as programmed cell death 1 ligand 1/2 (PD-L1/2), Fas ligand (FasL). This evidence concerns the gene FASLG and neoplasm.